Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Current Opinion in Lipidology|August 22, 2012
Proprotein convertase subtilisin/kexin type 9 inhibitionDavid A Marais, Dirk J Blom, Francine Petrides, et al.Current Opinion in Lipidology|July 3, 2013
The promises of PCSK9 inhibitionFrancine Petrides, Kate Shearston, Mathias Chatelais, et al.Atherosclerosis|December 25, 2012
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatmentArjan J Kwakernaak, Gilles Lambert, Maartje C J Slagman, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|September 12, 2015
Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on LymphangiogenesisRadjesh Bisoendial, Fatiha Tabet, Paul P Tak, et al.Journal of the American College of Cardiology|March 18, 2014
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defectsGilles Lambert, Francine Petrides, Mathias Chatelais, et al.Journal of the American College of Cardiology|May 12, 2012
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control studyRoeland Huijgen, S Matthijs Boekholdt, Benoit J Arsenault, et al.Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.Pageof 1